Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Y-mAbs Therapeutics Inc YMAB

Healthcare Biotechnology
Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of radioimmunotherapy and antibody-based therapeutic cancer products. Its technologies include its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform and bispecific antibodies generated using the Y-BiClone platform. Its advanced product... see more

Recent & Breaking News (NDAQ:YMAB)

Y-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate Developments

GlobeNewswire November 8, 2024

Y-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) in Japan

GlobeNewswire November 4, 2024

Y-mAbs Announces Third Quarter 2024 Conference Call and Webcast

GlobeNewswire October 25, 2024

Y-mAbs to Participate in Upcoming Investor Conferences in October

GlobeNewswire October 1, 2024

Y-mAbs Presents Neuroblastoma Research on Naxitamab and SADA PRIT Technology Platform at AACR Special Conference on Advances in Pediatric Cancer Research

GlobeNewswire September 6, 2024

Y-mAbs to Participate in Upcoming Investor Conferences in September

GlobeNewswire September 3, 2024

Y-mAbs Reports Second Quarter 2024 Financial Results and Recent Corporate Developments

GlobeNewswire August 12, 2024

Y-mAbs to Participate in Upcoming Investor Conferences in August

GlobeNewswire August 7, 2024

Y-mAbs Announces Second Quarter 2024 Conference Call and Webcast

GlobeNewswire August 5, 2024

Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial Officer

GlobeNewswire July 1, 2024

Y-MABS SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Y-mAbs Therapeutics, Inc. (YMAB) on Behalf of the Company's Long-Term Shareholders and Encourages Investors to Contact the Firm

Accesswire June 14, 2024

Y-mAbs Announces Preclinical GD2-SADA Data to be Presented at 2024 SNMMI Annual Meeting

GlobeNewswire June 7, 2024

Y-mAbs Deepens Radiopharmaceutical Leadership with Appointment of Norman LaFrance, M.D. as Chief Development Officer

GlobeNewswire June 5, 2024

Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual Meeting

GlobeNewswire June 1, 2024

Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual Meeting

GlobeNewswire June 1, 2024

Y-mAbs Reports First Quarter 2024 Financial Results and Recent Corporate Developments

GlobeNewswire May 7, 2024

Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024

GlobeNewswire April 26, 2024

Y-mAbs to Present at 2024 ASCO Annual Meeting

GlobeNewswire April 25, 2024

STOCK INVESTIGATION NOTICE: Kaskela Law LLC Announces Investigation of Y-mAbs Therapeutics, Inc. (YMAB) and Encourages Long-Term Investors to Contact the Firm

Newsfile April 15, 2024

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Y-mAbs Therapeutics, Inc. (YMAB) and Encourages Long-Term Investors to Contact the Firm for Additional Information

Newsfile April 2, 2024